2.00
price up icon12.99%   0.23
pre-market  Pre-mercato:  1.99   -0.01   -0.50%
loading
Precedente Chiudi:
$1.77
Aprire:
$1.83
Volume 24 ore:
3.87M
Relative Volume:
1.55
Capitalizzazione di mercato:
$93.16M
Reddito:
-
Utile/perdita netta:
$-37.65M
Rapporto P/E:
-1.1976
EPS:
-1.67
Flusso di cassa netto:
$-24.14M
1 W Prestazione:
+26.58%
1M Prestazione:
+49.25%
6M Prestazione:
+90.48%
1 anno Prestazione:
-51.34%
Intervallo 1D:
Value
$1.82
$2.0589
Intervallo di 1 settimana:
Value
$1.61
$2.0589
Portata 52W:
Value
$0.60
$4.83

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile

Name
Nome
Reviva Pharmaceuticals Holdings Inc
Name
Telefono
(408) 501-8881
Name
Indirizzo
10080 N WOLFE ROAD, CUPERTINO
Name
Dipendente
15
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
RVPH's Discussions on Twitter

Confronta RVPH con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RVPH
Reviva Pharmaceuticals Holdings Inc
2.00 93.16M 0 -37.65M -24.14M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-09-20 Iniziato ROTH MKM Buy
2023-06-08 Iniziato The Benchmark Company Speculative Buy
2022-01-24 Iniziato H.C. Wainwright Buy

Reviva Pharmaceuticals Holdings Inc Borsa (RVPH) Ultime notizie

pulisher
01:28 AM

Reviva Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RVPH) - MarketBeat

01:28 AM
pulisher
Jan 21, 2025

Reviva Pharmaceuticals Unusual Options Activity - Benzinga

Jan 21, 2025
pulisher
Jan 21, 2025

Traders Buy Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH) - MarketBeat

Jan 21, 2025
pulisher
Jan 21, 2025

Reviva Pharmaceuticals' (RVPH) Buy Rating Reiterated at D. Boral Capital - MarketBeat

Jan 21, 2025
pulisher
Jan 14, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Down 35.9% in December - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.25 - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Geode Capital Management LLC Buys 42,376 Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World

Jan 13, 2025
pulisher
Jan 12, 2025

Reviva Pharmaceuticals stock rated buy by Roth/MKM, backed by Phase 3 results - Investing.com Nigeria

Jan 12, 2025
pulisher
Jan 12, 2025

Roth Mkm Begins Coverage on Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World

Jan 12, 2025
pulisher
Jan 12, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to Buy at Maxim Group - Defense World

Jan 12, 2025
pulisher
Jan 12, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to “Strong-Buy” at Roth Capital - Defense World

Jan 12, 2025
pulisher
Jan 11, 2025

Maxim Group raises Reviva stock to Buy, sets new target By Investing.com - Investing.com Australia

Jan 11, 2025
pulisher
Jan 11, 2025

Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Target Price at $11.25 - MarketBeat

Jan 11, 2025
pulisher
Jan 11, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded at Roth Capital - MarketBeat

Jan 11, 2025
pulisher
Jan 10, 2025

Maxim Group Upgrades Reviva Pharmaceuticals (NASDAQ:RVPH) to Buy - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Roth MKM Initiates Coverage of Reviva Pharmaceuticals Holdings (RVPH) with Buy Recommendation - MSN

Jan 10, 2025
pulisher
Jan 10, 2025

Maxim Group raises Reviva stock to Buy, sets new target - Investing.com

Jan 10, 2025
pulisher
Jan 10, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Coverage Initiated at Roth Mkm - MarketBeat

Jan 10, 2025
pulisher
Jan 07, 2025

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit - Marketscreener.com

Jan 07, 2025
pulisher
Jan 07, 2025

Reviva Pharmaceuticals CEO to Present at Lytham Partners Healthcare Summit 2025 - StockTitan

Jan 07, 2025
pulisher
Dec 28, 2024

Reviva Pharmaceuticals to Participate in the UBS Global Healthcare Conference - Marketscreener.com

Dec 28, 2024
pulisher
Dec 26, 2024

What is Zacks Small Cap’s Estimate for RVPH FY2024 Earnings? - Defense World

Dec 26, 2024
pulisher
Dec 25, 2024

FY2024 Earnings Forecast for RVPH Issued By Zacks Small Cap - MarketBeat

Dec 25, 2024
pulisher
Dec 23, 2024

RVPH: Preliminary OLE Readout - Yahoo Finance

Dec 23, 2024
pulisher
Dec 19, 2024

Reviva Pharmaceuticals Strengthens Financial Position with Offering - Yahoo Finance

Dec 19, 2024
pulisher
Dec 18, 2024

Reviva Pharmaceuticals Announces Positive Preliminary Data from RECOVER Trial – - Defense World

Dec 18, 2024
pulisher
Dec 18, 2024

Reviva announces pricing of $18M public offering of common stock and warrants - MSN

Dec 18, 2024
pulisher
Dec 17, 2024

Reviva Pharmaceuticals Shares Slide Premarket After Stock Offering - MarketWatch

Dec 17, 2024
pulisher
Dec 17, 2024

CNS Drug-Maker Reviva Announces $18M Public Offering of Common Stock and Warrants to Fund R&D - geneonline

Dec 17, 2024
pulisher
Dec 17, 2024

Why Mitek Systems Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket - Benzinga

Dec 17, 2024
pulisher
Dec 16, 2024

Reviva Pharmaceuticals Announces $18M Public Offering with Warrant Package to Fund R&D Pipeline - StockTitan

Dec 16, 2024
pulisher
Dec 16, 2024

Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants - GlobeNewswire

Dec 16, 2024
pulisher
Dec 16, 2024

Reviva Announces Proposed Public Offering - The Manila Times

Dec 16, 2024
pulisher
Dec 16, 2024

Reviva Pharmaceuticals Launches Public Offering to Fund CNS Drug Development Pipeline - StockTitan

Dec 16, 2024
pulisher
Dec 16, 2024

Reviva Pharmaceuticals Reports Positive Phase 3 Trial Results - TipRanks

Dec 16, 2024
pulisher
Dec 16, 2024

Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia - The Manila Times

Dec 16, 2024
pulisher
Dec 16, 2024

Reviva Announces Positive Preliminary Topline Data for the - GlobeNewswire

Dec 16, 2024
pulisher
Dec 16, 2024

Reviva's Brilaroxazine Shows Promising Long-Term Results in Phase 3 Schizophrenia Trial - StockTitan

Dec 16, 2024
pulisher
Dec 15, 2024

Reviva Pharmaceuticals Holdings, Inc. Holds Annual Meeting and Approves Increase in Authorized Shares - Defense World

Dec 15, 2024
pulisher
Dec 13, 2024

Largest borrow rate increases among liquid names - TipRanks

Dec 13, 2024
pulisher
Dec 13, 2024

Reviva Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RVPH) - Defense World

Dec 13, 2024
pulisher
Dec 11, 2024

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low - Seeking Alpha

Dec 11, 2024
pulisher
Nov 30, 2024

Analyzing Reviva Pharmaceuticals (NASDAQ:RVPH) and Akebia Therapeutics (NASDAQ:AKBA) - Defense World

Nov 30, 2024
pulisher
Nov 19, 2024

RVPH: Year-End OLE Update - Yahoo Finance

Nov 19, 2024
pulisher
Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Reviva Pharmaceuticals Holdings Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Schonfeld Strategic Advisors LLC Increases Stake in Reviva Pharm - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Reviva Pharmaceuticals Holdings Inc. Warrants (RVPHW) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 14, 2024

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Nov 14, 2024

Reviva Pharmaceuticals Holdings Inc Azioni (RVPH) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
Capitalizzazione:     |  Volume (24 ore):